BR112022025190A2 - Construtos de anellovirus em tandem - Google Patents
Construtos de anellovirus em tandemInfo
- Publication number
- BR112022025190A2 BR112022025190A2 BR112022025190A BR112022025190A BR112022025190A2 BR 112022025190 A2 BR112022025190 A2 BR 112022025190A2 BR 112022025190 A BR112022025190 A BR 112022025190A BR 112022025190 A BR112022025190 A BR 112022025190A BR 112022025190 A2 BR112022025190 A2 BR 112022025190A2
- Authority
- BR
- Brazil
- Prior art keywords
- anellovirus
- tandem
- constructs
- nucleic acid
- acid construct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038483P | 2020-06-12 | 2020-06-12 | |
| US202163146963P | 2021-02-08 | 2021-02-08 | |
| PCT/US2021/037091 WO2021252955A1 (en) | 2020-06-12 | 2021-06-11 | Tandem anellovirus constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022025190A2 true BR112022025190A2 (pt) | 2023-03-07 |
Family
ID=78845951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022025190A BR112022025190A2 (pt) | 2020-06-12 | 2021-06-11 | Construtos de anellovirus em tandem |
Country Status (12)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3121528A1 (en) | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes and methods of use |
| TW202529819A (zh) | 2023-10-13 | 2025-08-01 | 美商旗艦先鋒創新公司 | 組織特異性指環載體(anellovector)遞送 |
| WO2025160409A1 (en) | 2024-01-26 | 2025-07-31 | Flagship Pioneering Innovations V, Inc. | Viral vectors for modulating vegf function |
| CN119331914A (zh) * | 2024-10-17 | 2025-01-21 | 中科开浦生物科技(湖北)有限公司 | 一种指环病毒感染性克隆的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2593189B1 (fr) * | 1986-01-22 | 1989-10-20 | Pasteur Institut | Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida |
| RU2553223C2 (ru) * | 2009-08-21 | 2015-06-10 | Виргиния Тек Интеллекчуал Пропертиз, Инк. | ВАКЦИНЫ НА ОСНОВЕ СВИНОГО ВИРУСА Torque teNO И СПОСОБЫ ДИАГНОСТИКИ ИНФЕКЦИЙ, ВЫЗВАННЫХ ЭТИМ ВИРУСОМ |
| ES2777217T3 (es) * | 2013-06-17 | 2020-08-04 | Broad Inst Inc | Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias |
| RU2744193C2 (ru) * | 2015-10-16 | 2021-03-03 | Канзас Стейт Юниверсити Рисерч Фаундейшн | Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения |
| CA3066750A1 (en) * | 2017-06-13 | 2018-12-20 | Flagship Pioneering Innovations V, Inc. | Compositions comprising curons and uses thereof |
| CA3121528A1 (en) * | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes and methods of use |
| JP2022513459A (ja) * | 2018-12-12 | 2022-02-08 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | タンパク質代替治療モダリティを送達するためのアネロソーム |
| EP3894567A2 (en) * | 2018-12-12 | 2021-10-20 | Flagship Pioneering Innovations V, Inc. | Anellosomes for delivering intracellular therapeutic modalities |
-
2021
- 2021-06-11 AU AU2021288320A patent/AU2021288320A1/en not_active Abandoned
- 2021-06-11 CA CA3186894A patent/CA3186894A1/en active Pending
- 2021-06-11 IL IL298978A patent/IL298978A/en unknown
- 2021-06-11 KR KR1020237001349A patent/KR20230036110A/ko not_active Ceased
- 2021-06-11 CN CN202180057194.7A patent/CN116075591A/zh active Pending
- 2021-06-11 EP EP21822876.5A patent/EP4165198A4/en not_active Withdrawn
- 2021-06-11 WO PCT/US2021/037091 patent/WO2021252955A1/en not_active Ceased
- 2021-06-11 TW TW110121557A patent/TW202223095A/zh unknown
- 2021-06-11 BR BR112022025190A patent/BR112022025190A2/pt unknown
- 2021-06-11 US US18/009,557 patent/US20230348933A1/en not_active Abandoned
- 2021-06-11 MX MX2022015802A patent/MX2022015802A/es unknown
- 2021-06-11 JP JP2022576004A patent/JP2023530278A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL298978A (en) | 2023-02-01 |
| WO2021252955A1 (en) | 2021-12-16 |
| MX2022015802A (es) | 2023-03-28 |
| US20230348933A1 (en) | 2023-11-02 |
| CN116075591A (zh) | 2023-05-05 |
| KR20230036110A (ko) | 2023-03-14 |
| EP4165198A4 (en) | 2024-10-23 |
| TW202223095A (zh) | 2022-06-16 |
| AU2021288320A1 (en) | 2023-01-19 |
| EP4165198A1 (en) | 2023-04-19 |
| CA3186894A1 (en) | 2021-12-16 |
| JP2023530278A (ja) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gogrefe et al. | Structure of a functional cap-binding domain in Rift Valley fever virus L protein | |
| BR112022018854A2 (pt) | Composições e métodos de rna circular | |
| BR112022026311A2 (pt) | Nucleases crispr-cas de ocorrência não natural para edição de genoma | |
| BR112022015628A2 (pt) | Vacina de sars-cov-2 | |
| BR122021025194A8 (pt) | Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna | |
| BR112018010635A2 (pt) | linhagens celulares estáveis para a produção retroviral | |
| BR112021020727A2 (pt) | Materiais e métodos para produção de proteína | |
| BR112018011059A2 (pt) | synp161, um promotor para a expressão específica de genes em fotoreceptores de haste | |
| BR112018002395A2 (pt) | variantes de promotor, ácido nucleico do promotor operacionalmente ligado a uma sequência de sinal e uma sequência que codifica uma proteína,construção de expressão, célula hospedeira quecompreende tal construção de expressão, e métodode produção de uma poi | |
| MX2022015802A (es) | Construcciones de anellovirus en tandem. | |
| BRPI0916355B8 (pt) | Vetor recombinante compreendendo um polinucleotídeo isolado, e, método para produzir um precursor de piripiropeno a | |
| BR112018010639A2 (pt) | método de transfecção transitória para produção retroviral. | |
| MX2010008052A (es) | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas. | |
| PE20211238A1 (es) | Tratamiento antisentido del sindrome de angelman | |
| BR112022010095A2 (pt) | Proteínas gpcr de opsina quimérica | |
| WO2022008510A3 (en) | Intron-encoded extranuclear transcripts for protein translation, rna encoding, and multi-timepoint interrogation of non-coding or protein-coding rna regulation | |
| MX2022015208A (es) | Constructos de acido nucleico para fabricacion de proteinas. | |
| AR065282A1 (es) | Composiciones y metodos que utilizan arn de transferencia de genes tipo cad para el control de nematodos | |
| BR112018068890A2 (pt) | dna polimerases marinhas | |
| CO2022013638A2 (es) | Enzimas para la sialilación de glicanos | |
| AR103921A1 (es) | Moléculas de ácido nucleico de ii33 de arn polimerasa para el control de plagas de insectos | |
| BR112023019757A2 (pt) | Proteína de fusão imunogênica | |
| BR112022022967A2 (pt) | Processo de purificação de proteínas provenientes da clara do ovo de galinha e seu uso como agente antiviral contra sars-cov-2 | |
| WO2021202443A3 (en) | Compositions and methods for silencing dnajc15 gene expression | |
| UY40243A (es) | Ácido nucleico aislado que codifica una proteína de fusión basada en fviii-bdd y en un péptido señal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |